PD-1(Programmed Death-1) Antibody +GP as First Line Treatment for Triple Negative Breast Cancer(TNBC) Patients
Clinical trial NCT03251313 · UNKNOWN
Trial details
- NCT number
- NCT03251313
- Sponsor
- Fudan University
- Status
- UNKNOWN
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2019-05-15
- Primary completion
- 2022-12-30
- Enrollment
- 31
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.